Kolinpharma S.P.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Composition for the treatment and prevention of urinary tract infections (US 10,300,099) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Composition for the treatment of neuropathies and/or neuropathic pain (US 10,413,526) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Composition for the treatment of arthropathies and osteoarthritis (US 10,548,937) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Composition having a muscle-relaxant and anti-inflammatory activity (US 10,583,120) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,548,937 | Composition for the treatment of arthropathies and osteoarthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,583,120 | Composition having a muscle-relaxant and anti-inflammatory activity In force · From the USPTO record | In force | From the USPTO record | |
| US 11,090,287 | Composition for the prevention and treatment of metabolic disorders associated with menopause and climacteric In force · From the USPTO record | In force | From the USPTO record | |
| US 9,980,940 | Composition for the treatment of neuropathies and/or neuropathic pain In force · From the USPTO record | In force | From the USPTO record | |
| US 10,300,099 | Composition for the treatment and prevention of urinary tract infections In force · From the USPTO record | In force | From the USPTO record | |
| US 10,413,526 | Composition for the treatment of neuropathies and/or neuropathic pain In force · From the USPTO record | In force | From the USPTO record | |
| US 12,329,724 | Composition based on L-tryptophan, resveratrol and crocus sativus extract for the treatment of menstrual cycle disorders In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 no status recorded